RedChip @RedChip

Watch Now: Comprehensive Healthcare Systems $CMHSF CEO Interview on Healthcare SaaS and Pipeline Growth In our exclusive interview, CEO Chris Cosgrove breaks down the company’s strategy to scale in the healthcare benefits administration market, a multibillion-dollar opportunity. For investors looking at underfollowed healthcare SaaS names, our interview lays out the compelling growth strategy, margin profile, and market opportunity. Watch our full interview: redchip.news/4rWX7kf $CMHSF $CHS $VEEV $GEHC $PME $TDOC $DOCS $HIMS $CERT $DH $TEM $ALKT

Exclusive Interview: $BESS Co-CEO Bob Brilon Breaks Down Bimergen’s $250M Backing, 2GW BESS Pipeline, and Scalable Growth Strategy Utility-scale battery storage is one of the fastest-growing segments in energy, and @BimergenEnergy is stepping up with a 2GW pipeline, $250M equity commitment, and contract-backed revenue model. Watch our full interview now: redchip.news/3MYl23K $BESS $NEE $FLNC $STEM $BE $ENPH $TSLA $GNRC $EOSE

ASP Isotopes $ASPI: CEO Paul Mann Outlines a Scalable Critical Materials Growth Story @ASPIsotopes is targeting some of the most important supply chains in the world, including nuclear medicine, nuclear fuel, semiconductors, and advanced materials. What stands out: • Three plants built in South Africa over three years • Commercial ramp expected in 2026 • U.S. expansion strategy aimed at securing supply of critical materials historically sourced from Russia • Exposure to multiple high-value end markets with growing geopolitical relevance Watch our full $ASPI investor overview: redchip.news/4eoGlGE $ASPI $SMR $NNE $OKLO $UUUU $CEG $VST $CCJ $UEC $LEU $GEV $BEP

Greenwich LifeSciences, Inc. (Nasdaq: $GLSI): CEO Snehal Patel Discusses GP2 Immunotherapy and Phase III Strategy In our most recent interview, CEO Snehal Patel outlines the company’s clinical and strategic roadmap for GP2, an immunotherapy designed to prevent breast cancer recurrences in HER2-positive patients following surgery. Key Takeaways for Investors: • Robust Phase IIb Data: GP2 achieved over 80% reduction in recurrence rates over five years, significantly outperforming existing therapies in the adjuvant setting. • Strong Safety Profile: No serious adverse events reported across 146 patients in four clinical trials. • Global Phase III Trial: FLAMINGO-01 is enrolling up to 750 patients across 150 clinical sites in the US and Europe in partnership with leading oncology networks. Hear directly from leadership about how Greenwich LifeSciences is positioning GP2 for commercial success and long-term impact. redchip.news/4uXA0ag $GLSI $PFE $LLY $JNJ $NVS $AZN $PBYI $BNTX $MRK $HOLX $IMCR

Anixa Biosciences $ANIX: Breast Cancer Vaccine Program Advances Following Phase 1 Clinical Milestone Breast cancer represents a $38B+ market opportunity, projected to reach nearly $90B by 2030. Anixa Biosciences is advancing a first-in-class breast cancer vaccine program developed with Cleveland Clinic and funded by the U.S. Department of War. $ANIX is targeting one of oncology’s largest markets with a capital-efficient biotech model and a vaccine platform designed to both treat and potentially prevent breast cancer. Watch our 30-second investor brief: redchip.news/3QIc3oT $ANIX $PFE $LLY $JNJ $NVS $AZN $PBYI $BNTX $MRK $HOLX $IMCR

ASP Isotopes (Nasdaq: $ASPI): Noble Africa to Merge with ENDRA Life Sciences, Creating a Dedicated Nasdaq-Listed Helium Platform for Renergen's Virginia Gas Project ASP Isotopes is moving to spin out its helium exposure into a standalone public vehicle. Noble Africa LLC — ASPI's intermediate holding company for Renergen — will merge with ENDRA Life Sciences (Nasdaq: $NDRA), with the combined entity expected to trade on Nasdaq under the ticker "NOBA." A concurrent private placement is expected to generate approximately $50 million in gross proceeds to fund Phase 1 and Phase 2 development of Renergen's Virginia Gas Project, with ASPI committing approximately $20 million as lead investor. Why investors are paying attention: - ~$50M concurrent private placement secured, including ~$20M from ASPI as lead investor and ~$30M from outside investors including $750,000 from ASPI directors and management - Upon closing, ASPI expected to own approximately 89% of the combined Noble Africa Inc., preserving substantial stockholder exposure to the Virginia Gas Project - Proposed Merger targeting a Nasdaq listing provides direct public market access to one of the few dedicated helium development platforms globally - Renergen's Virginia Gas Project is supported by up to $750M in committed debt financing, including funding from the U.S. Development Finance Corporation (DFC) - Transaction expected to close Q3 or Q4 2026, subject to SEC registration statement effectiveness and ENDRA stockholder approval Read the full PR: redchip.news/44wfPoI $ASPI $SMR $NNE $OKLO $UUUU $CEG $VST $CCJ $UEC $LEU $GEV $BEP

Virax Biolabs (Nasdaq: $VRAX): Early Pilot Data Validates ViraxImmune™ — U.S. LDT Launch Targeted for 2027 There are an estimated 21 million Americans living with post-acute infection syndromes — Long COVID, ME/CFS, post-treatment Lyme disease — and there is currently no widely adopted objective diagnostic test for any of them. CEO James Foster walked investors through the VRX 003 pilot data: 88% specificity and 92% positive predictive value across 120+ subjects — measurable separation between PAIS patients and healthy controls. The commercial pathway is defined: a U.S. laboratory-developed test launch targeted for 2027, built around a capital-efficient central lab model. No FDA IVD approval required to get there. At just 1–2% annual incidence penetration, management's framework points to $13–26M in potential annual revenue. Watch Now: redchip.news/4oDmA1i $VRAX $DGX $LH $EXAS $QDEL $HOLX $IDXX $BRKR $TDOC $CERS $FLGT $NOTV

Foremost Clean Energy $FMST: Athabasca Basin Uranium Explorer Positioned Against a Shifting Nuclear Policy Backdrop Foremost Clean Energy is actively drilling in the Athabasca Basin, the world's highest-grade uranium jurisdiction, across a 330,000+ acre portfolio backed by the technical expertise of their partners. Why investors are watching: - U.S. policy now targets 4x current nuclear capacity - Strategic partnership with Denison Mines provides historical drilling data and geological expertise across all 10 properties - $9M 2026 exploration budget with active drill programs underway - Nasdaq-listed, tight float of 10.6M shares, zero long-term debt Learn more: redchip.news/3PYvXf5 $FMST $DNN $CCJ $UEC $NXE $UUUU $RIO $SQM $ALB

⚡ First Phosphate (OTCQX: $FRSPF | CSE: PHOS): A $94M Acquisition Just Put Igneous Phosphate on the Map — And There Are Only Two Independent Players Left CEO John Pasel joined RedChip to discuss what Agnico Eagle's entry into igneous phosphate means for the sector — and why First Phosphate may be one of the most differentiated critical mineral stories in North America. 💡 LFP batteries now represent close to 80% of batteries produced globally. First Phosphate is purpose-built for that supply chain — from igneous rock to battery cell — using fully North American critical minerals. ▶️ Watch the full interview: redchip.news/3Q7yB29 $FRSPF $FPHOY $PHOS $MOS $NTR $VALE $IFOS $DAN $CXM

Alliance Entertainment: Executive Chairman Bruce Ogilvie on Strategy & Execution $AENT's growth priorities: scaling higher-margin exclusive content, expanding direct-to-consumer fulfillment, and leveraging automation to enhance profitability. Why Investors Should Watch: • Insight into how $AENT aligns operational execution with long-term shareholder value, targeting durable growth across premium entertainment and collectibles segments. Learn more: redchip.news/45Pnuj1 $AENT $FNKO $SONY $DIS $PARA $WBD $NTDOY

BioVie (Nasdaq: BIVI): 2 Clinical Assets, Multiple Catalysts, Multi-Billion-Dollar Market Targets BioVie is advancing a differentiated pipeline focused on neurodegenerative disease and liver disease, with CEO Cuong Do outlining why investors are watching the next phase of the company’s development. BioVie is operating at the intersection of large patient populations, high unmet need, and potential multi-billion-dollar commercial opportunities, including estimated U.S. market opportunities of $30B in Alzheimer’s, $3B in Parkinson’s, and $1.6B in ascites. For investors tracking clinical-stage biotech catalysts, BIVI is well worth a closer look. Watch the full CEO-guided overview: redchip.news/4dbyBG3 $BIVI $SXTP $INAB $DMAC $BFRG $NSRX $CLDI $NXL $CNTB $LTRN $KYNB $ANIX

⚛️ Rare earth elements are essential inputs for advanced industrial systems, including power generation, communications infrastructure, defense technologies, and high-performance manufacturing. Avalon Advanced Materials Inc. (TSX: AVL | OTCQB: AVLNF) is advancing the Nechalacho Rare Earth Project, one of the most strategically significant rare earth assets in North America, with both light and heavy rare earth content. 🔗 Learn more about Avalon’s rare earth strategy: redchip.news/43hXOtY S&P Global Energy Breaking Defense TechCrunch #AVL #AVLNF #InvestorWebinar #CriticalMinerals #SmallCapStocks #EVMaterials

NioCorp Developments $NB: CEO Mark Smith on 2025 Progress and the Advancing Path to Construction at Elk Creek $NB CEO Mark A. Smith reviews a pivotal year for NioCorp Developments — covering $370.8M raised in 2025, the launch of the $45M Mine Portal Project, advancing U.S. Export-Import Bank financing, and a Pentagon-funded partnership with Lockheed Martin and Skunk Works on scandium defense technology. Watch the full CEO interview: redchip.news/4nNyoOd $NB $MP $ARA $ILU $PPTA $TECK $KGC $USGO $NG $THM $WRN $HL $GPH $NST $FVL $CTGO

New Horizon Aircraft (Nasdaq: $HOVR): Leadership Team Heads to Farnborough International Airshow 2026 Horizon Aircraft will participate in the Farnborough International Airshow from July 20–24, 2026 — one of the world's premier aerospace and defence events — where its senior leadership team will engage with global operators, regulators, defense stakeholders, and industry partners on the Cavorite X7. Co-Founder and CEO Brandon Robinson is also scheduled to speak on the event's eVTOL panel on July 23rd, placing Horizon directly in front of an audience evaluating the next generation of vertical lift platforms. Read the full announcement: redchip.news/4evHqwm $HOVR $XTIA $UMAC $RCAT $NOC $LHX $BA $AVAV $KTOS $ONDS $PLTR $NVDA

Comprehensive Healthcare Systems (OTCQB: $CMHSF | TSXV: CHS): Novus360 Platform Lands Teamsters Local 237 Benefits Administration Contract CHS has signed a new five-year agreement with the Teamsters Local 237 Welfare and Retirees Benefit Fund — one of the largest Teamsters-affiliated benefit organizations in the U.S. — marking the company's third new five-year contract in six months. Collectively, these three agreements represent approximately US$12.1 million (C$17 million) in total contract value. Why investors are paying attention: - Teamsters Local 237 represents approximately 25,000 active members and more than 7,000 retirees across New York City municipal agencies, public-sector organizations, and healthcare institutions - New contracts expected to contribute approximately US$2.4M in average annual revenue over their five-year terms - Order book now at approximately US$27M (C$38M) as CHS targets US$100M in total signed contracts by 2028 - Teamsters Local 237 establishes a reference client within the broader International Brotherhood of Teamsters ecosystem, representing approximately 1.3 million members in North America Read the full PR: redchip.news/4oKplOi $CMHSF $CHS $VEEV $GEHC $PME $TDOC $DOCS $HIMS $CERT $DH $TEM $ALKT

Calidi Biotherapeutics $CLDI: RedTail Systemic Virotherapy Platform Advances Toward IND Submission as CEO Eric Poma Outlines the Investment Case $CLDI CEO Eric Poma, PhD explains how Calidi's proprietary RedTail platform addresses one of oncology's most persistent challenges: delivering oncolytic virotherapy systemically to metastatic tumors without immune clearance eliminating the therapy before it reaches its target. Watch the full interview: redchip.news/49n0biy $CLDI $PFE $AMGN $JNJ $CADL $BMRN $CPRX $CGON $REPL $NBTX $IBRX

Money still moves slower than data. Stablecoins change that—and OBOOK Holdings (OwlTing Group; Nasdaq: $OWLS) is building the rails to make it work inside the financial system. Hear directly from the CEO on why @OwlTing Group is positioning itself as the backbone of next-gen global payments. Full article + interview: redchip.news/3O3Gkgl $OWLS $COIN $PYPL $SQ $NATL $MARA $RIOT $MSTR $NVDA

🧬 Virax Biolabs (Nasdaq: VRAX): A Clinical-Stage Diagnostics Company Targeting a $25B+ Unmet Need in Post-Acute Infection Syndromes Up to 21 million Americans are living with Long COVID, ME/CFS, and post-treatment Lyme disease — yet there is currently no widely adopted objective diagnostic test for these conditions. Virax Biolabs is developing ViraxImmune™, a potential first-in-category immune profiling test designed to objectively assess immune dysfunction in chronic post-infection conditions — with U.S. commercialization planned for 2027. ViraxImmune™ is informed by UK NHS-linked clinical studies and independent U.S. validation work conducted at Emory University. 🎥 Watch our 30-second investor brief on Virax Biolabs: redchip.news/4wGnWMg $VRAX $PACB $VYGR $PFE $MRK #VRAX #ViraxBiolabs #LongCOVID #MECFS #Diagnostics #Biotech #Nasdaq #Investing

Comprehensive Healthcare Systems $CMHSF | $CHS combines recurring SaaS revenue, strong retention, and contract growth in a healthcare market still dominated by legacy systems. In our investor overview, CEO Chris Cosgrove explains how CHS is modernizing benefits and pension administration through its Novus 360 platform across the Taft-Hartley union and self-funded employer markets. For investors looking for underfollowed healthcare technology companies with sticky revenue and scalable economics, $CMHSF is a story worth a closer look. Watch our full overview: redchip.news/4coRPra $CMHSF $CHS $VEEV $GEHC $PME $TDOC $DOCS $HIMS $CERT $DH $TEM $ALKT